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Abstract: Unicellular eukaryotes of the Trypanosomatidae family include human and animal
pathogens that belong to the Trypanosoma and Leishmania genera. Diagnosis of the diseases they cause
requires the sampling of body fluids (e.g., blood, lymph, peritoneal fluid, cerebrospinal fluid) or
organ biopsies (e.g., bone marrow, spleen), which are mostly obtained through invasive methods.
Body fluids or appendages can be alternatives to these invasive biopsies but appropriateness remains
poorly studied. To further address this question, we perform a systematic review on clues evidencing
the presence of parasites, genetic material, antibodies, and antigens in body secretions, appendages,
or the organs or proximal tissues that produce these materials. Paper selection was based on searches
in PubMed, Web of Science, WorldWideScience, SciELO, Embase, and Google. The information of
each selected article (n = 333) was classified into different sections and data were extracted from 77
papers. The presence of Trypanosomatidae parasites has been tracked in most of organs or proximal
tissues that produce body secretions or appendages, in naturally or experimentally infected hosts. The
meta-analysis highlights the paucity of studies on human African trypanosomiasis and an absence
on animal trypanosomiasis. Among the collected data high heterogeneity in terms of the I2 statistic
(100%) is recorded. A high positivity is recorded for antibody and genetic material detection in urine
of patients and dogs suffering leishmaniasis, and of antigens for leishmaniasis and Chagas disease.
Data on conjunctival swabs can be analyzed with molecular methods solely for dogs suffering canine
visceral leishmaniasis. Saliva and hair/bristles showed a pretty good positivity that support their
potential to be used for leishmaniasis diagnosis. In conclusion, our study pinpoints significant gaps
that need to be filled in order to properly address the interest of body secretion and hair or bristles for
the diagnosis of infections caused by Leishmania and by other Trypanosomatidae parasites.
Int. J. Mol. Sci. 2020, 21, 1684; doi:10.3390/ijms21051684 www.mdpi.com/journal/ijms
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1. Introduction
Unicellular eukaryotes of the Trypanosomatidae family include human and animal pathogens
that belong to the Trypanosoma and Leishmania genera (including Endotrypanum) (Figure 1). Leishmania
and possibly Trypanosoma are probably descended from the parasites of blood-sucking insects that
survived accidental transmission to a vertebrate host during feeding [1]. They possess a complex life
cycle that includes arthropod vectors belonging to the Hemiptera and Diptera orders. Two Trypanosoma
subspecies of T. brucei (i.e., Trypanosoma brucei gambiense, T. brucei rhodesiense) and T. cruzi, along with
21 species of Leishmania, are pathogenic for humans. They cause human African trypanosomiasis
(HAT or sleeping sickness), Chagas disease (CD), and cutaneous (CL), muco-cutaneous (MCL), or
visceral (VL) leishmaniases [2–5]. Occasional infections in humans with T. evansi, T lewisi, T. brucei
brucei, or T. congolense have been described, but little is known about the public health importance of
these diseases [6]. In addition to their impact on human health, these diseases also affect domestic,
feral, or wild animals. Canine visceral leishmaniases (CVL) are mainly caused by L. infantum infection
and occasionally by L. donovani or L. major. Trypanosoma congolense, T. evansi, T. b. brucei, T. vivax,
T. simiae, T. suis, and more rarely, T. godfreyi, affect livestock, causing animal trypanosomiasis, and
T. equiperdum affects equids [7,8] (Figure 1). Altogether, more than 30 million people are infected with
these pathogens, and approximately 100,000 persons die every year from Trypanosoma brucei spp.,
T. cruzi, or Leishmania spp. infections [9]. An estimated 48 million cattle are at risk of contracting animal
trypanosomiasis in Africa. African animal trypanosomiasis (AAT) causes about 3 million deaths in
cattle every year (http://www.fao.org/paat/the-programme/the-disease/en/).
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Figure 1. Classification of human and animal pathogenic trypanosomatids. Human pathogenic 
species are underlined, and pathogens causing systemic infection are in bold. Figure 1. Classification of human and animal pathogenic trypanosomatids. Human pathogenic species
are underlined, and pathogens causing systemic infection are in bold.
Leishmaniases rank after malaria in terms of annual incidence and affect 98 countries and
territories worldwide. Visceral leishmaniasis kills between 20,000 and 30,000 persons annually; 1
million cutaneous leishmaniasis cases have been reported over the past five years, and over 1 billion
people live at risk of infection (http://www.who.int/leishmaniasis/en/). Leishmania spp. are obligate
intracellular protozoan parasites transmitted mainly by two genera of sandflies, namely, Phlebotomus
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and Lutzomyia [4]. Sexual transmission of Leishmania species responsible for canine and human
visceral leishmaniases is documented [10–13], as well as blood transmission in dogs and transmission
between drug users through contaminated needles [14,15]. Congenital transmission was first described
in 1926 and is more frequently reported today [16,17]]. Following Leishmania infection, metacyclic
promastigotes are rapidly engulfed (macrophages and dendritic cells) and then disseminate from the
skin to the spleen, liver, and bone marrow myeloid cells [18]. Leishmania causes cutaneous or visceral
aﬄictions. Cutaneous lesions vary in their severity (e.g., lesion size), numbers, clinical appearance
(e.g., dry or wet lesion) and incubation time (e.g., the time for spontaneous cure) [19]. Nevertheless, at
least in an experimental model of infection, some Leishmania species responsible for cutaneous forms
have the capacity to disseminate into internal organs [20]. Most of the patients infected with L. donovani
and L. infantum develop only subclinical disease or chronic latent infections without any clinical
manifestation [21,22]. In patients, irregular fever, splenomegaly, pancytopenia, hepatosplenomegaly,
and hypergammaglobulinemia characterize visceral leishmaniasis. Atypical disseminated leishmaniasis
might be observed in Leishmania–HIV coinfected persons, with parasites colonizing the gastrointestinal
mucosa, the respiratory tract, and the liver [19]. In addition to human diseases, leishmaniasis affects
dogs, where it provokes a deadly disease if not treated. Lymphadenomegaly, a loss of body condition,
pale mucous membranes, splenomegaly, alopecia, furfur, and onychogryphosis are the most frequently
observed clinical signs, but many other clinical features, alone or combined, such as polyuria/polydipsia,
diarrhea, fever, arthropathy, or ocular lesions, can be present [23–25].
Chagas disease, also known as American trypanosomiasis, is caused by T. cruzi and has been
reported in all Latin American countries, where it constitutes the most important parasitic infection and
has emerged as a disease of importance outside of endemic areas, largely as a result of migration [26,27].
Six to seven million people are estimated to be infected with the parasite, but the disease burden may
be underestimated, as evidenced at least in Mexico [28]. Trypanosoma cruzi is mainly transmitted to
humans and other mammals by hematophagous insects called triaomines or kissing bugs belonging to
the subfamily Triatominae [27]. Nevertheless, the parasite can also be transmitted via non-vectorial
routes, such as blood transfusion, congenital transmission, organ transplantation, ingestion of food
and beverages contaminated with T. cruzi (oral transmission; a typical example is the ingestion of fruit
juice contaminated by triaomine feces, frequently reported in the Amazonian region [29], or laboratory
accidents. Sexual transmission was also recently documented in a murine model, but there is no
evidence of such a mechanism of transmission in humans [30]. Inside its host, T. cruzi is internalized
in the cells of the immune system. Once an individual acquires the parasite, the infection develops
progressively. Chagas disease has two clinical phases. The first, called acute phase, is characterized
by a high parasitaemia in patients’ blood. During this phase, the parasite undergoes multiplication
and infects local macrophages, fibroblasts, and muscle cells. During this phase, the patients have
generally no or only mild nonspecific symptoms (e.g., fever). Nevertheless, some acute cases (2–6%)
can lead to death due to myocarditis and meningoencephalitis, mostly in children. Accute cases
can also be observed following organ transplantation [31] or HIV infection [32]. The second phase
of the infection is known as chronic phase. At the beginning of this phase, the parasites remain
hidden in the body, and there are no clinical or physical signs. However, over the years, 30–40%
of patients develop clinical symptoms. Chronic chagasic cardiomyopathy is the most frequent and
serious clinical manifestation leading to heart failure or sudden death [33]. Other patients present
digestive (megaesophagus, megacolon among others) or neurological alterations or a combination
of them [33,34]. Urinary tract disorder and dysfunction is documented in patients with cardiac and
digestive Chagas Disease [35].There is evidence of functional and structural kidney abnormalities
after T. cruzi infection, associated with reduction in renal blood flow, proximal tubular damage, and
inflammatory interstitial infiltrate [36,37]. In immune compromised patients cutaneous lesions caused
by reactivation of T. cruzi is also described [38].
Sleeping sickness is caused by trypanosomes transmitted by tsetse flies (Glossina spp.). The overall
number of infected people is approximately 10,000 [39]. The disease presents two distinct forms,
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chronic and acute, which are caused by two distinct trypanosome subspecies, transmitted by two
distinct vector species. The chronic form, caused by T. brucei gambiense, is distributed in western and
central Africa and is transmitted mainly by Glossina palpalpalis sp., while the acute form, caused by
T. brucei rhodesiense, is distributed in east Africa and is transmitted mainly by Glossina morsitans species.
Bites of infected tsetse flies and the injection of salivarian trypanosomes often result in the formation of
skin ulceration (chancre). During the first stage of the disease (stage 1, known as the hematolymphatic
stage), the trypanosomes are present and multiply in the blood and in the lymph nodes. Stage 2, the
meningo-encephalitic stage, begins after the invasion of the central nervous system (CNS) [40,41]. An
early symptom of T. b. gambiense infection is hypertrophy of the lymph nodes, which corresponds
to a multiplication of parasites within the lymphatic system. Parasites can be seen in the lymph
nodes of the cervical chain after a puncture of the ganglion. During this invasive phase of the disease,
lesions are observed in the liver, the spleen, the cardiovascular and endocrine system, as well as the
eyes [42,43]. Heart abnormality cases are scarce, but in cases of occurrence, they can provoke acute
and fatal cardiac damage by arrhythmia, mainly in T. b. rhodesiense-infected patients. T. b. gambiense
infection can cause persistent and dissociated tachycardia and atrioventricular rhythm or signs in
favor of early myocarditis or pericarditis [44–48]. In addition, descriptions of cutaneous symptoms
associated with African trypanosomiasis and distinct “trypanid” skin lesions are documented [49–51].
The ability of Trypanosoma brucei to survive at the epidermis interface is reported in experimental
infection models [52,53]. They have also been observed in slides of historical skin biopsies taken as a
part of a diagnostic screening program for Onchocerca microfilariae in the trypanosomiasis-endemic
region of the Democratic Republic of the Congo [52].
In addition to human African trypanosomiasis, animal trypanosomiasis (AT; nagana, surra,
dourine) affects livestock (cattle, small ruminants, and pigs), equids (horses, donkeys) and camelids
(camels, dromedaries, llamas, and alpacas). They give rise to important economic losses in Africa, the
Middle East, Asia, and Latin America [7,54]. In addition to their cyclical transmission by tsetse flies
(Glossina sp.), trypanosomes infecting animals can also be transmitted mechanically by blood-sucking
insects (mainly stomoxines and tabanids) and even directly via venereal transmission in the case
of dourine [54–56]. In cattle and small ruminants, most cases are caused by Trypanosoma congolense
and T. vivax, but infection by a variety of other trypanosomes and mixed infections are also frequent.
Trypanosoma evansi affects horses and camels and can affect other mammals [56]. Trypanosoma brucei
s. l. might have a minor role in the pathogenesis of cattle even if it is often isolated in the blood
of infected animals. Trypanosoma godfreyi is rare and was first described in the midgut of tsetse flies
caught in Gambia [57]. Trypanosoma simiae and, rarely, T. suis have been identified in livestock, but
their precise role in the disease remains unclear [58]. Trypanosoma equiperdum is venereally transmitted
and appears to be restricted to horses and donkeys. Trypanosoma evansi is the trypanosome species that
presents both the widest variety of described hosts, including rodents, ruminants, equids, camelids,
and humans [56], and the largest diversity in transmission modes, including cyclical via tsetse flies,
mechanical via blood-sucking flies and vampire bats, possibly sexual, and via contaminated meat or
carcasses [54–56]. Under experimental conditions, T. congolense can be mechanically transmitted by
biting flies (e.g., tabanids and stomoxines) [59], the epidemiological consequence of which in nature is
not clear, and currently, only T. evansi and T. vivax have adapted to mechanical transmission and spread
beyond the tsetse transmission zone in livestock industries of Asia (T. evansi) and South America
(T. vivax, T. evansi) [60]. Overall, African animal trypanosomiasis remains one of the most important
infectious disease constraints to livestock production in sub-Saharan Africa. The hallmarks of clinical
signs reminiscent of animal trypanosomiasis infection include ventral edema, emaciation, anemia,
and neurological symptoms [61,62], but there is no dichotomy in the clinical evolution as for human
infections, probably because trypanosomes can be found in all body fluids of animals (blood, lymph,
CSF, urine, aqueous humor, synovium). Overall, animal trypanosomiases remain among the most
important infectious disease constraints to livestock production in sub-Saharan Africa, as well as Latin
America and Asia.
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The methodologies used for typing trypanosomatidae parasites and diagnosing infections are
summarized in Table 1. Microscopic examination of biopsy represents the simplest methodological
approach to diagnose infection and detect pathogens. The hard identification at the species/subspecies
level and its low sensitivity are limitations. Like microscopic examination, the in vitro parasite
cultivation presents the advantage of being relatively simple to perform but has low sensitivity
and requires sophisticated laboratory equipment. Xenodiagnosis is more complex than the other
parasitological approaches but does not require biological sampling. Molecular methods involved
polymerase chain reaction (PCR) or isothermal amplification of the genetic material. PCR is relatively
simple to perform and to visualize. Refinements in PCR technologies included the development of
nested PCR and of multiplexed PCR methodologies that have increased sensitivity and discriminative
capacity of the test. Other refinements in the detection of the amplified product include PCR–ELISA
(enzyme-linked immunosorbent assay). PCR–RFLP (restriction fragment length polymorphism)
allows the detection of the variation between DNA fragments patterns, generated by restriction
enzyme digestion caused by alternative nucleotides at the restriction sites that can be used for
Leishmania and trypanosome species discrimination. PCR–HRM (high resolution melting) detects
double-stranded DNA (dsDNA) alternatives by ascertaining changes in the fluorescence intensity, of a
DNA-intercalating dye, during the dissociation process of dsDNA to single-stranded DNA (ssDNA). It
was applied with success to Leishmania and T. cruzi detection and species and Discrete Typing Unit
(DTU) delineation [63,64]. Oligochromatography-PCR (OC–PCR) provides a simple and rapid format
for the detection of PCR or nucleic acid sequence-based amplification (NASBA) products, visualized on
a dipstick by hybridization with a gold-conjugated probe. This detection format takes only 5–10 min
and requires no equipment other than a water bath and a pipette [65,66]. Loop-mediated isothermal
amplification (LAMP) uses the strand displacement activity of a DNA polymerase to amplify the
dsDNA target with four primers designed to recognize six distinct regions. Amplification is completed
in a single step at an isothermal temperature [67]. LAMP can be more sensitive than conventional
PCR for the detection of Leishmania and Trypanosoma species [68,69]. The dermal diagnostic tests or
Leishmanin skin test (LST)/Montenegro test is based on the delayed-type hypersensitivity (DTH)
reactions raised following intradermal injection of killed Leishmania promastigotes into the skin forearm.
It does not require biological sampling. Indirect immunofluorescence (IFAT) relies on the use parasites
layered on a fluorescent glass slide that is used to test the presence of anti-parasites antibodies in
the patient serum. This methodology was assayed for the serodiagnosis of Chagas disease, sleeping
sickness, leishmaniasis [70–72], and animal trypanosomiasis [73]. IFAT methodology is more used
for surveillance programs than for clinical diagnosis. Western blot allows us to visualize antigens
targeted during antibody response. It presents the advantage of being more sensitive and specific
than ELISA (see below). The direct agglutination test (DAT), further modified for detection of the
agglutination activity on a card (CATT), allows the visualization of the precipitin activity. It uses
whole micro-organisms as a means of looking for serum antibodies. CATT is a commonly serological
test for HAT and is still in use for AAT serodiagnosis [74,75]. The agglutination methodology can
also be performed with antibody-coated latex beads to trap antigen. KAtex, a commercialized latex
agglutination test, is developed for the diagnosis of visceral leishmaniasis and uses a specific Leishmania
antibody coated on latex particles [76]. Enzyme-linked immunoabsorbent assays (ELISA) can be
performed to detect and quantify antibodies or antigens in samples. Alternatively, sandwich ELISA
can be used to detect the circulating parasite’s antigens, which informs on the ongoing infectious
process. Immunochromatography (ICT) or lateral flow test is based on a series of capillary beds that
have the capacity to transport fluid spontaneously. The analyte is deposited on the dipstick and then
spontaneously migrates to the first element that acts as a sponge to holds an excess of sample fluid.
Once soaked, the fluid migrates to the second element in which the antibody or antigen is present in
conjunction with colored particles. The analyte migrates to the third component of the test, in which
antibodies are immobilized to stop the flow.
Int. J. Mol. Sci. 2020, 21, 1684 6 of 49
Table 1. Methodologies to diagnose Chagas disease (CD), animal trypanosomiases (AT), human African trypanosomiasis (HAT), and leishmaniosis, and/or to detect
their respective causative agents.
Methodologies Quantification Culture
CD
Detection
and
Identification
AT
Detection
and
Identification
HAT
Detection
and
Identification
Leishmania
Detection
and
Identification
Ref
D
N
A
/R
N
A
-b
as
ed
M
et
ho
ds
PC
R
PCR/qPCR/Multiplex yes no yes/DTU yes/sp yes/sp yes/sp [77–79]
PCR–OC no no NA/NA yes/sp yes/sp yes/sp [80,81]
PCR–ELISA yes no NA/NA yes/sp yes/sp yes/sp [82–85]
PCR–HRM no no yes/DTU NA/NA NA/NA yes/sp [63,86]
PCR–RFLP no no yes/DTU yes/sp yes/sp yes/sp [87–89]
PCR-sequencing no no yes/DTU yes/sp yes/sp yes/sp [78,88]
O
th
er
PFGE no yes yes/NA yes/sp yes/sp no/sp [88,90,91]
NASBA no no NA/NA NA/NA yes/sp yes/sp [81]
LAMP poss no yes/no yes/sp yes/sp yes/sp [69,92]
N
on
D
N
A
-b
as
ed
M
et
ho
ds
Pa
ra
si
to
lo
gy
Microscopic examination yes no yes/no yes/no yes/no yes/no [2,19,27,93]
In vitro parasite culture no yes yes/no yes/no yes/no yes/no /
Isolation in experimental
animals no no yes/no NA/NA yes/no yes/no /
Xenodiagnosis no no yes/no NA/NA yes/no yes/no [94–97]
Dermal diagnostic tests no no NA/NA NA/NA NA/NA yes/no [98]
Im
m
un
ol
og
y/
Se
ro
lo
gy
ELISA Ab no no yes/no yes/no yes/no yes/no [99–101]
ELISA Ag no no yes/no yes/no NA/NA yes/no [102]
IFAT no no yes/no yes/no yes/no yes/gen [71–73,103,104]
ICT Ag no no NA/NA NA/NA NA/NA yes/gen [105]
ICT Ab no no NA/NA NA/NA yes/no yes/no [106,107]
DAT/CATT no no yes/yes yes/yes yes/yes yes/yes [74,99,100,108]
Western blot no no yes/no NA/NA NA/NA yes/sp [109,110]
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Table 1. Cont.
Methodologies Quantification Culture
CD
Detection
and
Identification
AT
Detection
and
Identification
HAT
Detection
and
Identification
Leishmania
Detection
and
Identification
Ref
Pr
ot
ei
n-
ba
se
d
m
et
ho
ds
MLEE no yes no/DTU no/sp no/sp no/sp /
MALDI-TOF no yes no/DTU NA/NA no/sp no/sp [111,112]
gen: genera. sp: species. DTU: discrete typing unit. NA: not available. DAT: direct agglutination test. CATT: card agglutination test for trypanosomiasis. MLEE: multilocus enzymatic
electrophoresis. MALDI–TOF: matrix-assisted laser desorption ionization–time of flight. ICT: immunochromatographic test. ELISA: enzyme-linked immunosorbent assay. PCR–OC:
polymerase chain reaction with oligochromatography. LAMP: loop-mediated isothermal amplification. Ab: antibody. Ag: antigen. PFGE: pulse field gel electrophoresis. NASBA: nucleic
acid sequence-based amplification. PCR: polymerase chain reaction. HRM: high melting resolution. RFLP: restriction fragment length polymorphism.
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Hematogenous dissemination and tissue tropism are part of the infectious process of
trypanosomatid pathogens. During the blood-feeding process, trypanosomatid pathogens are injected
(Leishmania, salivarian trypanosomes) or deposited (stercorarian trypanosomes) on the skin of the host.
Following their introduction into the bloodstream, they disseminate into specific organs or tissues and
multiply. In these infections, as in a majority of other infections, pathology often correlates with the
sites of accumulation of the infectious agent, but variations in disease outcomes and presentations are
also related to the interaction between host and parasite [113–116]. The selection of the appropriate
biopsy site for diagnoses relates to the physiopathology of the diseases, reflecting the disseminative
capacity (tissue or organ tropism) of these pathogens within its host. Therefore, the diagnosis of these
diseases requires the sampling of body fluids (e.g., blood, lymph, peritoneal fluid, cerebrospinal fluid)
or organ biopsies (e.g., bone marrow, spleen), which are mostly obtained through invasive methods.
Alternative biological samples, such as body secretions (e.g., milk, saliva, urine, semen, nasal secretion,
lacrimal fluid, earwax, sweat, feces) or appendages (e.g., nail, hair, bristles) that are constantly produced
might be an interesting alternative to invasive biopsies. Non-invasive biological sampling that does
not require trained professionals and are easy and safe to collect would render the diagnosis more
convenient. We address the interest of such biological material via a systematic review of the published
literature and meta-analysis on data extracted from a defined pool of published papers.
2. Results and Discussion
2.1. Study Selection
In the primary search, 2932 documents were identified via PubMed, and additional screening
with other databases allowed the selection of another 1386 documents. After duplicate removal, 1530
documents were screened for relevance according to their titles and abstracts; at this stage, 1153
documents were omitted. The full text of the 377 studies was carefully read, and the ineligible (n = 44)
documents were omitted. The 333 remaining manuscripts were included in the systematic review. Data
could be extracted from 77 articles. A diagram of the study plan, following the PRISMA statement, is
given in Figure 2.
2.2. Systematic Review of Non-Invasive Sampling Strategies for the Diagnosis and Detection of Trypanosomatid
Pathogens and Infections
2.2.1. Urine
Urine is an easy-to-collect secretion that is produced daily. Therefore, a large amount of information
has been gathered on the presence of trypanosomatid parasites within this liquid.
Human and animal leishmaniases. The survival capacity of Leishmania, and T. cruzi in urine has
been known since 1966 [117]. In vitro, urine can promote the growth of the Leishmania promastigote
and can be used as a low-cost culture adjuvant alternative to serum [118]. The first evidence of the
presence of Leishmania in the urine of patients infected by L. donovani came in the 1930s through
the detection of Leishman–Donovan bodies in the urine of infected patients [119]. The presence
of viable Leishmania parasites in the urine of infected individuals is documented [120–122]. The
crossing of the glomerular barrier by Leishmania is thought to be a consequence of VL renal lesions
and renal failure [123,124]. Tubulointerstitial involvement and glomerulonephritis are the main
causative agents of the proteinuria disorder, which is common in most patients with a clinical
episode of leishmaniasis [125–127]. In infected individuals, urine represents a fluid from which
parasite DNA is easily extracted for detection and species identification [128], which has been probed
in the urine of patients [109,121,129,130] and in animal reservoirs [131,132]. These searches were
performed in VL caused by L. infantum [109,120,121,133]; in CL and VL-HIV+ patients infected by
L. martiniquensis [134]; in CL due to L. major or L. tropica [109]; in South American cutaneous and
mucocutaneous leishmaniasis caused by L. braziliensis, L. guyanensis, or L. peruviana [130]; and in
canine visceral leishmaniasis [131,132,135]. The presence, in urine, of precipitin activities directed
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against several microorganisms has been known since 1948 [136]. The nature of these activities was
formerly attributed to antibodies in 1965 [137]. In 1983, the presence of anti-Leishmania antibodies
in urine was demonstrated [138,139]. Since then, the anti-Leishmania antibody response in patient
urine to diagnose VL has been further investigated. ELISA, which uses recombinant antigens or
whole antigen preparations as well as the direct agglutination test (DAT), has been used to test for
disease diagnosis using patient urine [105,139–147]. Immunochromatographic tests to detect rk39
antibodies are currently commercialized and have been thoroughly tested in urine [105,144,148–150].
Antibodies present in urine directed against rKP42, a kinesin-related protein and a homolog of rK39,
also showed remarkable sensitivity and specificity for VL [151]. This specificity and sensitivity were
comparable to those obtained with ELISA performed using acetone-treated L. donovani promastigote
antigens or DAT [139,140]. The detection of the antibody response against Leishmania infection, due
to L. major, L. tropica, or L. infantum, was also investigated using Western blot [109,152]. IgA or
IgG are detected in the urine of dogs suffering from leishmaniasis [153], where antibodies directed
against L. infantum are present [154–156]. Because of the persistence of antibodies after cure, these
tests cannot be used to diagnose VL in people with a past history of VL. A search for Leishmania
proteins in urine has therefore been undertaken [138,152,157–159], as well as for changes in the urinary
proteome of infected individuals [160]. In L. infantum-infected patients, iron superoxide dismutase,
L. infantum tryparedoxin, and L. infantum nuclear transport factor 2 (Li-ntf2) were identified by mass
spectrometry analysis [158,159]. When used in a multiplex ELISA test, these biomarkers show a
sensitivity superior to 80% for VL diagnosis caused by L. infantum but fail to accurately diagnose VL
due to L. donovani [158,159]. In L. donovani-infected patients, two biomarkers showing a sensitivity
of approximately 82% were characterized [161]. A low-molecular-mass heat-stable leishmanial
carbohydrate antigen [162] has allowed the development of a latex agglutination test (KAtex) to be
commercialized [76,162] and compared to ELISA [163]. Its efficiency was thoroughly tested in various
VL endemic areas [76,105,129,148,164–169]. The KAtex test in urine might be useful for the detection of
VL within the clinical case definition: fever for more than two weeks, splenomegaly, and no previous
history of VL [170]. As a simple field-deployable Leishmania urine antigen test, the capacity of this
test to predict initial treatment failure and relapse was investigated. Overall, this preliminary study
showed that the test may be used for risk stratification of initial treatment failure and VL relapse in HIV
patients [171]. A meta-analysis of these various tests has been recently performed [170,172]. Overall,
these meta-analyses point out that the rK39 assay provides the highest sensitivity and that the ELISA
has the highest specificity for the diagnosis of VL [172].
Human African trypanosomiasis and animal trypanosomiases. No information on the presence
of DNA, antibodies, or antigens in the urine of human individuals affected by sleeping sickness was
collected during the systematic review. The sole evidence on the presence of genetic material in urine
comes from an experimental infection of vervet monkeys by T. brucei. In this model, Trypanosoma DNA
could be amplified from urine, with LAMP as early as 17 days postinfection [173]. Biochemical changes
associated with trypanosome infection have been published on animal models infected by various
Trypanosoma species. Rabbits infected by parasites of the T. brucei subgroup showed a progressive
increase in proteins released in the urine [174]. The presence of fibrinogen and fibrin degradation
products in the urine of rabbits infected by T. brucei is suggestive of a glomerular permeability
change [175]. Mice or Microtus montanus infected by T. b. gambiense showed an increase in the
excretion of aromatic amino acid catabolites [176–179]. In mice infected with T. evansi, the concentration
in phenylpyruvic acid, 4-hydroxyphenylpyruvic acid, and indole-3-pyruvic acid correlates with
parasitemia and returns to normal following suramin treatment [180]. These metabolites were also
detected in dogs and donkeys experimentally infected [180]. The high rate of aromatic amino acid
catabolism by African trypanosomes was associated with the large decrease in free serum levels of
aromatic amino acids and with alterations in host tyrosine and phenylalanine metabolism. These
events correlate with the pathology of sleeping sickness and the depletion reported in certain amino
acids (tryptophan), which would lead to the depletion of essential metabolites such as serotonin
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and the toxicity of end products such as phenylpyruvate, reviewed in [181]. Changes in the urinary
proteome of patients suffering from sleeping sickness were observed, notably, in proteins related to
several infectious processes. These changes can be the rationale for developing non-invasive tools
aimed at tracking the disease stage [182]. In animal models, T. brucei parasites were observed in the
kidney glomeruli of infected rats, and T. lewisi in the kidney capillaries [183,184]. T. musculi, a parasite
specific to mice, resides in the blood and lacks intracellular stages. After immune clearance of the
flagellates from the general circulation, mice became resistant to reinfection. However, long after
parasites were no longer detected in the peripheral blood, they still persisted in the vasa recta of the
kidneys in a peculiar biological stage [185], releasing molecular determinants in the urine as potential
diagnostic biomarkers.
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Chagas Disease. Evidence on the capacity of T. cruzi to survive in urine came along with those
on Leishmania [117], and T. cruzi amastigotes have been occasionally detected in the kidney [186].
Parasite DNA was detected in the urine of experimentally infected pigs (Sus scrofa) or mice [187–189].
The crossing of T. cruzi to urine in experimentally infected mice is apparently independent of renal
injuries [189]. The presence of DNA in urine is associated with the presence of parasite DNA in blood
and heart and with a high level of parasite DNA in blood, but not with the presence of parasites in
kidney or kidney injury [189–191]. The detection of antigens within the urine of patients suffering
from acute [192] or chronic CD [193] has opened up some new innovative approaches for diagnosis.
A number of T. cruzi urinary antigens can be identified and classified according to their molecular
weight, such as the 80 kDa iron-binding protein or the 150–160 kDa antigen. These antigens were
detected by the use of antibodies raised against an immunodominant epitope of T. cruzi. In addition,
parasite tubulin was also detected in urine as well as a set of immunoreactive antigens [192,194–196].
In mice, cruzipain, a major cysteine protease of T. cruzi, was detected in urine [187]. To develop a
diagnostic test based on a capture ELISA system, a panel of polyclonal antibodies was produced
against membrane antigens or trypomastigote excreted/secreted antigens. The test performed on
urine from patients positive for ELISA capture against sera demonstrated a 100% positivity [197].
Antigens are present in urine at low concentrations and are susceptible to degradation after collection.
These characteristics limit the sensitivity and reliability of all urinary-based antigen detection. The
use of nanoporous hydrogel particles produced with poly(N-isopropylacrylamide) (poly(NIPAm))
and N,N9-methylenebisacrylamide (BAAm) coupled to chemical baits via amidation reaction has
the potential to concentrate and preserve the antigens [198] for its application using urine [199]. The
test, called Chunap (Chagas urine nanoparticle test), has been further developed and evaluated for
congenital transmission of T. cruzi [200]. In this condition, it showed more than 90% sensitivity and
more than 95% specificity [200]. It also demonstrated good sensitivity in HIV–T. cruzi coinfected
cases [201].
2.2.2. Feces
Human and Animal Leishmaniases. Most of the references that document the findings of Leishmania
in human feces were published during the 1920s and l930s [202,203]. Anecdotally, descriptions of the
presence of L. tarentolae in feces of the Tarentola mauritanica lizard were published approximately at the
same time [204]. The detection of Leishmania amastigotes and its DNA in the feces of a dog infected by
L. infantum was documented [205]. More recently, a screening of wild gorilla fecal samples revealed
the presence of promastigotes and amastigotes of L. major within these samples [206]. Nevertheless,
this finding has been a matter of debate [207,208]. More recently, a large diversity of trypanosomatid
parasites in the feces of great apes, but no Leishmania DNA, was evidenced [209]. Since the 1920s, at
the time Donovan bodies were detected in human feces, no additional information on the detection
of parasites or the DNA of Leishmania in human feces has been published. The only other clues on
the presence of Leishmania DNA in the human gut come from studies performed on pre-Columbian
mummies using next-generation sequencing. These analyses highlight the presence of DNA related to
Leishmania and T. cruzi, without being able to firmly identify Leishmania at the species level [210–212].
Human African Trypanosomiasis and Animal Trypanosomiases. The ITS1 region of T. b. brucei, T.
b. gambiense, T. b. rhodesiense, and T. b. evansi was successfully amplified from DNA isolated from fecal
samples of experimentally infected mice [213] and T. b. rhodesiense and/or T. b. gambiense DNA was
detected in the feces of wild gorillas [209,213].
Chagas Disease. Megacolon is a pathological aﬄiction that occurs in chagasic patients [34].
Evidence of the presence of T. cruzi DNA in the gut of pre-Columbian mummies is documented,
depicting that the disease has a long evolutionary history with humans in South America [210–
212,214,215]. The tissue tropism of various T. cruzi isolates was investigated in a mouse model of
infection. In these experiments, parasite DNA was detected in the small intestine and rectum of the
animals [216,217]. In infected mice, the gut is the primary site of parasite persistence in the BALB/c
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model of chronic Chagas disease and is associated with a perturbation in the gut microbiome [218,219].
In opossums (Didelphis marsupialis), one of the multiple wild reservoirs of T. cruzi, the developmental
cycle that usually occurs in the intestine of the triatomine vector can take place in the anal odoriferous
glands [220]. In human feces, to our knowledge, no information is currently published.
2.2.3. Saliva/Oral Swab/Sputum
Oral swab, saliva, and sputum are the easiest and least-invasive sampling methodology for the
detection of infectious pathogens. Although bronchoalveolar lavage is not considered a nonintrusive
method to collect biological samples, it does not cause damage to tissues.
Human and animal leishmaniases. The presence of viable Leishmania parasites in the saliva
of infected patients was demonstrated in 1934 by Forkner [221]. More recently, L. braziliensis was
recovered from the saliva of a person suffering from cutaneous leishmaniasis [222]. A large number
of studies describe the successful detection and identification of Leishmania DNA in saliva or oral
swabs, with PCR or other methodologies of DNA amplification (LAMP). The DNA was amplified in
L. martiniquensis-HIV positive and negative patients [134,223–226] but also in kala-azar patients infected
by L. donovani [227,228] and in dogs suffering from CVL [229,230]. In 1994, a report discussed the
presence of agglutinating anti-leishmania activity, an antibody, in the saliva of kala-azar patients [231].
The capacity of anti-leishmania antibodies present in the saliva to be used to diagnose CVL and VL
was investigated more recently. For CVL, the detection of IgG2 and IgA antibodies targeting specific
recombinant K39 protein (rK39) in saliva demonstrated the usefulness of this test to diagnose CVL and
to differentiate between seropositive and seronegative dogs [232]. In humans, a preliminary experiment
involving the detection of rK39 antibodies demonstrated 99.2% sensitivity and 100% specificity for
Leishmania diagnosis using patient sputum [149]. Interestingly, KAtex showed a higher sensitivity
to diagnose Mediterranean visceral leishmaniasis with oral fluid than with urine, even though this
test was originally conceived to be used with urine [129]. In addition to saliva, Leishmania has been
occasionally detected in the bronchoalveolar lavages of patients suffering from VL [233,234].
Human African Trypanosomiasis and Animal Trypanosomiases. Trypanosome-specific IgG can be
detected in the saliva of T. b. gambiense-infected HAT patients using ELISA. Nevertheless, the antibody
concentration is at least 250-fold lower in saliva than in serum [235]. The ELISA performed on the
saliva of a cohort of 208 individuals, including 78 parasitologically confirmed patients, demonstrated a
robust sensitivity and specificity (>90%) comparable with CATT performed on sera [236]. Since then,
no additional experiments have been performed.
Chagas Disease. The first evidence on the presence of T. cruzi in the saliva of experimentally
infected dogs dates from 1966 [117,237]. More recently, an ELISA that detected and quantified the IgG
response to T. cruzi was developed using saliva from infected patients. The methodology was tested
with success on saliva from patients with chronic infection, which is characterized by the absence of
blood circulating parasites [238,239]. The oral swab was also tested to detect fragments of Trypanosoma
DNA (Trypanosoma dionisii, T. rangeli, and T. cruzi) to evaluate the potential reservoirs for T. cruzi in
gallery forest bats [240].
2.2.4. Conjunctival Swab/Lacrimal Fluid/Occular
A swab is a small piece of soft material used for taking a small amount of substance from a body.
The conjunctival or corneal swab, a routine practice to perform biological sampling to diagnose eye
infection, has been applied to detect trypanosomatid pathogens.
Human and animal leishmaniases. In humans, ocular lesions are usually associated with systemic
signs [241–243]. Ocular pathologies are documented in patients suffering from cutaneous [244–249],
diffuse cutaneous [244,250] or post-kala-azar leishmaniasis [241], and in VL [251,252]. In dogs,
keratoconjunctivitis and kerato-uveitis are described as the most usual symptoms, occurring in
16–80% of affected dogs [253,254]; keratoconjunctivitis is also observed in feline leishmaniasis [255].
Leishmania has been isolated from the aqueous humor of a patient suffering from leishmaniasis [242].
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In addition, eyelid leishmaniasis is frequently described [247–249,256]. In naturally infected dogs,
anti-Leishmania IgG was detected in the aqueous humor, although at a level not related to the serum
level of IgG [257,258]. In dogs, histopathological investigations depicted the presence of plasmatic cells
and macrophages bearing amastigote forms of Leishmania, in the ciliary body, sclerocorneal limbus, iris,
and lacrimal duct, but also in smooth and striated muscles [257,259–261]. Leishmania were observed in
squamous carcinoma cells from conjunctival swab samples from a HIV+ patient [262]. Leishmania DNA
can be detected and quantified by qPCR in the lacrimal glands of symptomatic dogs [263]. All these
clues have prompted testing the efficiency of the conjunctival swab for CVL diagnosis [264–267] and
tracking asymptomatic dog infections [268] but also for diagnosing feline leishmaniasis [267,269,270].
In addition, the detection of Leishmania DNA in conjunctival swabs has also been applied to track
L. infantum wild reservoirs [271,272].
Human African Trypanosomiasis and Animal Trypanosomiases. In humans, eye pathologies
associated with trypanosome infections remain unusual [273], and an investigation for the presence of
parasites, DNA, or antibodies within conjunctival swabs has not been performed. In dogs infected by
T. b. brucei, the eyes are one of the most severely affected organs, and infection by T. evansi can provoke
blindness [274,275]. Experimental infections of cats with T. brucei [276] and of cats and goats with
T. evansi highlight their disseminative capacity in the eye, with their presence being detected in the
aqueous humor [277,278].
Chagas Disease. In 1935, Romana first described the “unilateral schyzotrypanosomic conjunctivitis”
associated with acute T. cruzi infection, later known as Romana’s sign [279]. The invasion of the human
host by T. cruzi occurs in various ways but mainly via skin lesions or the conjunctival way [280,281].
T. cruzi parasites deposited on the conjunctiva, via the manipulation of contaminated bug feces,
are drained with tears into the nasolacrimal duct and nasal cavity. Then, T. cruzi infects the most
proximal tissues lined with cuboidal and columnar epithelial cells [281,282]. Surprisingly, reports on
eye pathology in CD patients are very scarce. Recently, the first case of Trypanosoma cruzi–associated
retinitis was diagnosed [283]. The presence of T. cruzi amastigotes in the conjunctiva, corneal stroma, the
adjacent ocular muscle, and the interstitial macrophages of Thrichomys apereoides (Rodentia, Echimyidae)
experimentally infected with T. cruzi has been documented [284].
2.2.5. Genital Organs: Semen/Vulvular Secretion
Some trypanosomatid infections impact male and female reproductive organs, causing
infertility [285]. Leishmania infection provokes a decrease in sperm quality, genital lesions, testicular
amyloidosis, chronic prostatitis, and epididymal inflammation [285]. Chagas disease is associated with
male hormonal changes and a loss in sperm quality due to parasitic load. In females, the invasion of
the placenta and hormonal changes are associated with the overproduction of inflammatory cytokines
in the oviduct and uterus. In sleeping sickness, an impairment in the spermatogenic cycle due to
damage in the pituitary gland as well as damage to the reproductive organs is reported. In females,
impairment in the estrus cycle due to pituitary gland damage is noticed [285].
Human and animal leishmaniases. Leishmaniasis does not belong to the broad list of potential
sexually transmitted infections (STIs). Nevertheless, some evidence suggests that venereal transmission
of leishmaniasis does occur in dogs and humans [10,286–288]. In humans, lesions in the male genitalia
are well documented [289–291], with the presence of parasites [292,293]. In dogs, genital lesions
associated with visceral leishmaniasis and the shedding of Leishmania sp. in the semen of naturally
or experimentally infected dogs has been described and can lead to infertility [122,294,295]. In
the prepuce and glans of male symptomatic dogs, heavy parasite burden has been detected and is
associated with inflammation, testicular degeneration, atrophy, an absence of spermatogenesis, and
necrosis [296]. In these dogs, immunohistochromatography showed that 75% of symptomatic dogs
and 35% of asymptomatic dogs were positive for Leishmania in the testis. These percentages rose to
95% and 60% for symptomatic and asymptomatic leishmaniasis, respectively, in the epididymal duct.
The detection of Leishmania parasites in semen has been evidenced through parasite culture [108],
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microscopic observation or immunohistology [294,296], and polymerase chain reaction [294,295,297].
A CVL experimental infection of 8 female dogs pinpoints that vulvar swab is at least as sensitive as an
oral swab for the detection and quantification of Leishmania kDNA, and this methodology is proposed
to confirm Leishmania infection in seropositive dogs [298]. The presence of L. infantum amastigotes in
the genital tract of naturally infected bitches has been documented [299].
Human African Trypanosomiasis and Animal Trypanosomiases. In humans suffering from
sleeping sickness, sterility or infertility, menstrual disorder, a loss of libido, impotence, and amenorrhea
have been reported [300]. Testicular damage and clinical manifestation have been described [301], and
sexual transmission has been very occasionally observed [302]. Trypanosoma equiperdum, responsible for
dourine, is a sexually transmitted disease of Equidae [303–305]. A loss of fertility is observed in infected
animals and is associated with the detection of parasites in semen [306,307]. For Trypanosoma vivax, in
addition to tsetse flies, transmission routes include transplacental and sexual routes, and parasites were
detected in the semen of infected animals [302,308]. In naturally acquired or experimentally induced
animal trypanosomiasis caused by T. brucei or T. congolense, a decrease in semen production associated
with an alteration in spermatogenesis has been recorded [309–313]. Histological lesions characterized
by testicular degeneration, epididymitis, and epididymal epithelial hyperplasia were detected in
the same animals and suggest the participation of the parasite in the etiopathogenic mechanism of
reproductive damage, frequently reported in infected animals [308,310,314]. In experimentally infected
mice, bioluminescent imaging confirmed the localization of viable trypanosomes in infected mice [315]
with an accumulation in the epididymal adipose tissue and in the epididymis [316].
Chagas Disease. The main transmission route of T. cruzi is via reduviids, but sexual and
transplacental transmission have been described and have epidemiological relevance [317,318]. In
1911, Vianna described testis lesions in experimentally T. cruzi-infected guinea pigs [319]. Human
orchitis was described in 1916 [320]. The first evidence on the infection of the testis by T. cruzi during
the acute phase of the disease dates from 1982 [321]. Since then, experimental infection has further shed
light on the disseminative capability of this organism during the acute phase of the disease into the
male and female genital organs. In a mouse model of infection, T. cruzi was detected in the preputial
glands and skin, penis, testicular albuginea, epididymis, vas deferens, seminal vesicles, prostate, and
urethral glands [322,323]. In females, T. cruzi invades cells of the vagina, uterus, oviduct, ovary, and
clitoris [313,315]. In addition, T. cruzi DNA has been detected in the semen of patients suffering from
Chagas disease [317,324]. Limited data exist for humans, but the presence of T. cruzi was reported in
seminiferous tubules and ovarian cells of children who succumbed to Chagas disease and in menstrual
blood of infected patients [30,325].
2.2.6. Milk
The presence of parasites of the Trypanosomatidae family in milk has been probed in view of a
maternal transmission risk.
Human and animal leishmaniases. Attempts to test the capacity of Leishmania to survive and
proliferate in milk were undertaken as early as the 1930s; some evidence on the adequacy of this
medium to support Leishmania survival was published [326]. Histopathological investigation of
female dogs suffering from CVL probed the presence of Leishmania amastigotes in the mammary
glands [296]. Nevertheless, the presence of Leishmania in milk has not yet been reported in patients
suffering from leishmaniasis.
Human African Trypanosomiasis and Animal Trypanosomiases. The investigation of
trypanosomes in milk has a long history of research and had first focused on the risk of the transmission
of pathogens, mainly the risk of transmission of T. evansi. Evidence on the presence of T. evansi in the
milk of lactating cows comes from the work of Zwick and Fisher and was described by Henry and
Guilhon in 1944 [327]. During the 1910–1930 period, a set of experimental procedures was employed
to detect the presence of various species of Trypanosoma species in the milk of experimentally or
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naturally infected animals [328]. Nathan-Larrier reported that mice and rats experimentally infected
by T. equiperdum show trypanosomes in their milk [328].
Chagas Disease. Because T. cruzi, originally named Schyzotrypanum cruzi, possesses the capacity
to cross the epithelium and to infect via the oral route [29,327,329], the presence of this pathogen in the
milk has been searched for. T. cruzi was found in the milk of experimentally infected mice [328,330,331],
and several reports describe the presence of this pathogen in the milk from pregnant women [332–335],
as reviewed by Norman and Lopez-Vélez [336]. In most cases, the presence of T. cruzi in the milk of
pregnant women has been attributed to contamination by infected blood due to nipple bleeding [336].
Therefore, the capacity of T. cruzi to invade the mammary gland of infected females has been
undertaken. These histological investigations on mice demonstrate the presence of T. cruzi amastigotes
in the mammary gland alveoli, excretory ducts, the connective tissue envelope of the ducts, inter-
and intralobular connective tissue, histiocytes, adipose tissue, the sebaceous glands of the nipple,
striated muscle fibers beneath the nipple, and inside the duct lumen [337]. Such proximity of T. cruzi
parasites with colostrum or milk argues for the inactivation of T. cruzi by pasteurization or microwave
treatment [338,339].
2.2.7. Nasal Secretion
Human and animal leishmaniases. The presence of L. donovani parasites has been detected in the
nasal secretions of patients as early as 1936 and reconfirmed sixty years later [119,221]. Parasite DNA
can efficiently be detected in this secretion [230]. Parasite DNA has also been detected in the clinically
unaffected nasal mucosa of patients infected by L. braziliensis [340]. Among the clinical presentation of
human leishmaniasis, mucocutaneous alterations are described. They are mainly present in South
America and are caused by a restricted number of Leishmania species [4]. Nevertheless, this uncommon
presentation is also reported to be caused by some Old World species [341], suggesting that nasal
secretion deserves further investigation to be confirmed as a positive fluid for Leishmania detection.
Human African trypanosomiasis and animal trypanosomiases. No information gathered during
the study.
Chagas disease. No information gathered during the study.
2.2.8. Ear Swab/Cerumen
Human and animal leishmaniases. Leishmania DNA has been detected and quantified in the
cerumen of infected dogs [342]. A recent publication demonstrates that cerumen–qPCR expresses the
highest sensitivity (87.5%) to detect genetic materials, followed by hair (lesions: 78.57%, healthy skin:
62.5%), and blood (68.75%) [343]. The ear skin of infected dogs bears a high parasite load compared to
other corporal zones and tends to be more infective to sand flies than that of the abdomen [344]. The
usefulness of ear swab was investigated in CVL-positive dogs, and positivity of 43% was recorded [230].
In addition, ear lesions caused by L. mexicana (Chiclero’s ulcer) are known, but the lesions at this site
can be caused by other Leishmania species [345].
Human African trypanosomiasis and animal trypanosomiases. No information gathered during
the study.
Chagas disease. No information gathered during the study.
2.2.9. Hair/Bristles
Appendages such as hair, bristles, and nails are not referenced as target tissues for trypanosomatid
survival and proliferation. Therefore, only a few studies were performed using these materials for the
investigation of trypanosomatid infection.
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Human and animal leishmaniases. The first series of analyses were performed on dog hair by
searching for markers of infection via the analysis of volatile organic compounds. This approach is
based on the hypothesis that illnesses can modify odors exhaled by individuals [346] and that canine
Leishmania infection involves the liberation of some volatile compounds specific to the infection [347,348].
Therefore, with this methodology, it is not the infectious agent that is detected, nor the immunologic
response, nor the set of volatile compounds exhaled by the dogs. Although hair is not known
as a target tissue for Leishmania, an investigation of Leishmania DNA was undertaken on CVL in
a mouse experimental model of infection with L. major but also in the hair of wild mammals or
Leporidae [342,349,350]. In mice, the DNA of L. major is detected near the inoculation site but also
in hair collected in body areas far from the infection site [349]. The first evidence on the usefulness
of PCR performed on hair to act as a biomarker of infectiousness of the host came from CVL [351].
The rationale for such an accumulation of parasite DNA into the hair of the infected animal is not
entirely understood. The hypothesis of a transdermal elimination process has been raised. This process,
observed as a secondary component of primary skin diseases, includes the elimination of endogenous
substances but also exogenous infectious organisms, such as Mycobacterium tuberculosis or HIV [352]. It
requires the direct incorporation of the parasite DNA among skin and hair keratinocytes at the site of
inoculation. The intracellular infection of keratinocytes with Leishmania was not detected following the
infection of C57Black/6j mice [353], but the presence of Leishmania amastigotes has been observed in
the hair follicles of patients with cutaneous leishmaniasis [352].
Human African trypanosomiasis and animal trypanosomiases. No information gathered during
the study.
Chagas disease. No information gathered during the study.
2.3. Meta-Analysis of Non-Invasive Sampling Methodologies for Trypanosomatid Infection Diagnosis:
Overview and Limitations
Meta-analyses on value for the diagnosis of leishmaniasis, of rapid diagnosis tests (RDTs) of VL,
and on urine as a biological sample have recently been published [170,172]. The results from these
analyses disclose the interest of 2 tests, an antibody detection test (rK39), and an antigen detection
test (KAtex) for VL confirmatory diagnosis. Here, we performed a meta-analysis on the positivity
of various non-invasive methodologies for diagnosing human and animal infections with parasites
belonging to the Trypanosomatidae family, to delineate their potential as an alternative to invasive
biopsies for disease diagnosis and pathogen tracking. It is, therefore, a comparative study. Data were
extracted from selected papers according to the following criteria: (1) diagnosis performed on the
basis of clinical symptoms and confirmed by PCR, ELISA, IFI, or parasitology; and (2) data available
for individual subjects or grounded according to clinical symptoms and diagnosis confirmation (see
Section 4 for the methodology).
Overview and limitation of the collected data for meta-analysis. A large majority of studies
focus on urine as a biological sample, primarily in Leishmania infection and CD. Strikingly, in urine,
Leishmania parasites, antibodies, antigens, and genetic material have been tracked. A test based on
the detection of Leishmania antigen in urine is commercialized. Although the detection of antigens in
urine has been exclusively performed on human VL, a large majority of studies have focused on the
detection of DNA in human patients. For Chagas disease, the main area of investigation has been the
detection of T. cruzi antigen in urine, and the search for T. cruzi DNA is reported in only one publication,
but this discusses the detection of DNA in an experimental model of infection [179]. Surprisingly,
we did not find any information on the detection of HAT in the urine of human patients or on AAT.
Saliva is the second body secretion used to track Leishmania infection. In saliva, the search for the
presence of antibodies directed against T. cruzi is reported for CD. Saliva is also the sole body secretion
investigated for HAT diagnosis [235,236]. The third most investigated secretion is the lacrimal fluid
that is collected at the same time as conjunctival cells by the use of conjunctival swabs. All these studies
have been performed on dogs or cats or other mammals using PCR, qPCR, or PCR hybridization
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(kDNA). Finally, partial information on the presence of antibodies, antigens, DNA, or parasites is
currently published for other materials (e.g., feces, hair/bristle, milk, cerumen, nasal secretion). For all
these reasons, an exhaustive meta-analysis of all the alternative non-invasive biological samples for
diagnosis of diseases caused by Trypanosomatidae cannot be performed. Genetic material detection
has been tested in urine, saliva, nasal, cerumen, and conjunctival swab. Nevertheless, for conjunctival
swabs, data are available only for canine visceral leishmaniasis. Other limitations are the wild diversity
of methodological approaches used to diagnose the disease or to detect pathogens that have been
employed. Immunological approaches included antigen and antibody detection. Within these, the
agglutination test, ELISA, immunochromatography, or Western blot were used. For molecular methods,
PCR, qPCR, and LAMP were employed. For parasitological methods, in vitro culture or biopsy staining
were used. Lastly, some studies included HIV positive and negative patients. In this meta-analysis, we
cannot perform subgroup analysis by technical approaches or HIV status because of the lack of data to
perform it.
Overall data were extracted from 77 papers (see Table 2). A majority of papers (88%) focused on
Leishmania infection, 9.6% on Chagas disease, and 2.4% on HAT. Strikingly, we did not find studies
on AAT diagnosis with non-invasive biological sampling that can be included in this meta-analysis
(Table S3).
Within papers dealing with leishmanioses, more than 50% focused on VL due to L. infantum (syn
L. chagasi) to diagnose CVL. For CD, the majority of the studies discussed the use of urine to diagnose
the disease with immunological approaches, mainly antigen capture. Only two papers investigated
alternative biological sampling for sleeping sickness diagnosis and tested antibody-based detection in
the saliva.
Random effect meta-analyses were carried out using the total sample size and the number of
positive samples (effect size, standard error of effect size) to estimate the positivity of the non-invasive
sampling methods of each methodological approach. We therefore analyzed pooled estimates by
random effects analysis. The results of the heterogeneity test (Table 3) depict high heterogeneity in
terms of the I2 statistic (100%).
2.3.1. Urine
Urine is by far the most studied body secretion investigated for the presence of antibody, antigen,
parasite, or genetic material, mainly in Leishmaniasis and Chagas disease, for antigen detection.
Human and animal leishmaniases. A positivity of 59% (95% CI; 34–82%) is recorded when human
or dog urine are used to detected the genetic material in urine of human or dogs (Figure 3). The test of
heterogeneity between studies depicts high a heterogeneity (I2 = 93.57%). Subgroup analysis depict a
positivity rate of 61% (95% CI; 27–90%; I2 = 93.57%) for human urine, that is higher than those recorded
for dogs, 51% (95% CI; 38–64%) (Figure 3).
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Table 2. References and characteristics of the studies from which data can be extracted.
Ref Author/year Country Pathogen Host Clinic HIV Methodology Sample Sa Size
[119] Mebrahtu 1993 Kenya L. donovani Human VL No Parasitology U 64
[120] da Costa Lima 2018 Brazil L. infantum Human VL No Parasitology and geneticmaterial U 30
[133] Pessoa-E-Silva 2016 Brazil L. infantum Human VL Yes Parasitology U 18
[354] de Mendonça 2015 Brazil L. infantum Dog CVL NA Parasitology U 17
[130] Veland 2011 Peru Leishmania spp. Human CL-MCL No Genetic material U 86
[131] Solano-Gallego 2007 Spain andItaly L. infantum Dog CVL NA Genetic material U 43
[109] Mirzaei 2018 Iran Leishmania spp. Human VL-CL No Geneticmaterial-Immunology/Ab U 37
[168] Motazedian 2008 Iran L. infantum Human VL No Genetic material U 30
[121] Fisa 2008 Spain L. infantum Human VL Yes Genetic material U 17
[135] Franceschi 2007 NK Leishmania spp. Dog CVL NA Genetic material U 16
[167] Sundar 2005 India L. donovani Human VL No Immunology/Ag U 382
[144] Singh 2013 India L. donovani Human VL No Immunology/Ab-Ag U 365
[145] Chakravarty 2011 India L. donovani Human VL No Immunology/Ab U 280
[163] Vallur 2015
Ethiopia,
Bangladesh,
Sudan, Brazil
Leishmania spp. Human VL No Immunology/Ag U 166
[165] Rijal 2004 Nepal L. donovani Human VL No Immunology/Ab U 155
[105] Singh 2010 India L. donovani Human VL No Immunology/Ag-Ab U 150
[141] Islam 2008 Bangladesh L. donovani Human VL No Immunology/Ab U 115
[143] Khan 2010 Bangladesh L. donovani Human VL No Immunology/Ab U 100
[355] Ghosh 2016 Bangladesh L. donovani Human VL No Immunology/Ab U 87
[148] Diro 2007 Ethiopia L. donovani Human VL No Immunology/Ag-Ab U 87
[356] Vogt 2018 Ethiopia L. donovani Human VL No Immunology/Ag U 87
[140] Islam 2004 Bangladesh L. donovani Human VL No Immunology/Ab U 75
[156] Todolí 2009 Spain L. infantum Dog CVL NA Immunology/Ab U 64
[171] van Griensven 2018 Ethiopia L. donovani Human VL No Immunology/Ag U 63
[139] Islam 2002 Bangladesh L. donovani Human VL No Immunology/Ab U 62
[194] Umezawa 1993 Brazil T. cruzi Human CD No Immunology/Ag U 60
[76] Attar 2001 Brazil, Nepal,Yemen Leishmania spp. Human VL No Immunology/Ag U 59
[193] Katzin 1989 Argentina T. cruzi Human CD No Immunology/Ag U 58
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Table 2. Cont.
Ref Author/year Country Pathogen Host Clinic HIV Methodology Sample Sa Size
[169] Riera 2004 Spain L. infantum Human VL Yes Immunology/Ag U 49
[357] Fernández-Roldán 2017 Spain L. infantum Human VL No Immunology/Ag U 44
[146] Goswami 2012 India L. donovani Human VL-PKDL yes Immunology/Ab U 42
[358] Salam 2011 India L. donovani Human VL No Immunology/Ag U 36
[99] Sarkari 2008 Iran? Leishmania spp. Human VL No Immunology/Ag-Ab U 35
[129] Ben-Abid 2017 Tunisia L. infantum Human VL No Immunology/Ag U-S 35
[201] Castro-Sesquen 2016 Bolivia, Peru T. cruzi Human CD No Immunology/Ag U 31
[359] Corral 1998 Argentina,Paraguay T. cruzi Human CD No Immunology/Ab U 30
[360] García-García 2006 Spain L. infantum Human VL Yes Immunology/Ab U 28
[361] Abeijon 2018 Brazil L. infantum Human VL No Immunology/Ag U 24
[362] Cruz 2006 Spain L. infantum Human VL No Immunology/Ag U 23
[200] Castro-Sesquen 2014 Bolivia, Peru T. cruzi Human CD No Immunology/Ag U 23
[153] Zaragoza 2003 Spain L. infantum Dog CVL NA Immunology/Ag U 22
[363] Abeijon 2013 Brazil L. infantum Human VL No Immunology/Ag U 20
[138] Kohanteb 1987 Iran L. infantum? Human VL No Immunology/Ag-Ab U 21
[159] Abeijon 2012 Brazil L. infantum Human VL No Immunology/Ag U 19
[192] Corral 1996 Argentina T. cruzi Human CD No Immunology/Ag U 17
[166] Vilaplana 2004 Spain L. infantum Human VL yes Immunology/Ag U 16
[152] De Colmenares 1995 Spain L. infantum Human VL No Immunology/Ag U 15
[364] Abeijon 2016 India L. donovani Human VL No Immunology/Ag U 7
[197] Málaga-Machaca 2017 Peru T. cruzi Human CD No Immunology/Ag U 6
[227] Vaish 2011 India L. donovani Human VL No Genetic material S 148
[225] Pandey 2018 Thailand L. martiniquensis? Human VL Yes Genetic material S 130
[365] Boni 2017 Brazil Leishmania spp. Human CL-MCL No Genetic material S-N 15
[134] Phumee 2013 Thailand L. martiniquensis Human VL-CL No Genetic material andParasitology S-U 6
[238] Pinho 1999 Brazil T. cruzi Human CD No Immunology/Ab S 114
[235] Lejon 2003 DRC T. b. brucei Human SleepS No Immunology/Ab S 78
[236] Lejon 2006 DRC, Benin T. b. brucei Human SleepS No Immunology/Ab S 23
[25] Peña 2008 Spain L. infantum Dog CVL NA Parasitology O 60
[366] Aschar 2016 Brazil L. infantum Dog CVL NA Genetic material O-S 92
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Table 2. Cont.
Ref Author/year Country Pathogen Host Clinic HIV Methodology Sample Sa Size
[367] de Almeida Ferreira2012 Brazil L. infantum Dog CVL NA Genetic material O 80
[368] Di Muccio 2012 Italy L. infantum Dog CVL NA Genetic material O 72
[369] Solano-Gallego 2001 Spain L. infantum Dog CVL NA Genetic material O 67
[370] Ceccarelli 2014 Italy L. infantum Dog CVL NA Genetic material O 65
[230] Ferreira 2013 Brazil L. infantum Dog CVL NA Genetic material O-S-N 62
[266] Pereira 2016 Brazil L. infantum Dog CVL NA Genetic material O 60
[371] Carvalho Ferreira 2014 Brazil L. infantum Dog CVL NA Genetic material O 60
[229] Lombardo 2012 Italy L. infantum Dog CVL NA Genetic material O-S 57
[265] Ferreira 2008 Brazil L. infantum Dog CVL NA Genetic material O 46
[372] Geisweid 2013 Germany L. infantum Dog CVL NA Genetic material O 43
[268] Leite 2010 Brazil L. infantum Dog CVL NA Genetic material O 30
[264] Strauss-Ayali 2004 Israel L. infantum Dog CVL NA Genetic material O 24
[373] Pilatti 2009 Brazil L. infantum Dog CVL NA Genetic material O 23
[374] Gao 2015 China L. infantum Dog CVL NA Genetic material O 5
[269] Benassi 2017 Brazil Leishmania Cat ? NA Genetic material O 2
[350] Ortega 2017 Spain Leishmania Leporidae ? NA Genetic material H 65
[375] Belinchón-Lorenzo2016 Brazil L. infantum Dog CVL NA Genetic material H 30
[376] Belinchón-Lorenzo2013 Spain L. infantum Dog CVL NA Genetic material H 28
[351] de Sousa Gonçalves2016 Brazil L. infantum Dog CVL NA Genetic material H 15
Genetic material: refers to all molecular methodologies that amplify/quantify DNA or RNA independent of the molecular method of amplification. Immunology: refers to all methodologies
that use antibodies to detect/quantify antigen and vice versa. Parasitology: refers to methodologies involving parasite observation after in vitro culture, sedimentation, or staining of a
smear. CVL: canine visceral leishmaniasis. VL: visceral leishmaniasis. CL: cutaneous leishmaniasis. MCL: mucocutaneous leishmaniasis. CD: Chagas disease. SleepS: sleeping sickness.
NK: not known. NA: not applicable. U: urine. O: ocular. S: saliva. N: nasal. H: hair. C: cerumen/ear0. The only two studies gathered on T. brucei, in bold, were excluded from the
subgroup analysis.
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Table 3. Subgroup analysis and test for effect size heterogeneity.
Positivity (95% CI) Heterogeneity
df p I2 (%) Tau2
Positive PCR in Urine 0.73(0.63–0.84) 8 <0.0001 100 0.250
Positive Ab in Urine 0.57(0.37–0.76) 13 <0.0001 100 0.139
Positive Ag in Urine 0.59(0.47–0.72) 28 <0.0001 100 0.117
Positive Parasite in Urine 0.85(0.80–0.91) 5 <0.0001 100 0.004
Positive PCR in
Conjunctival Swab 0.56(0.30–0.81) 17 <0.0001 100 0.306
Positive PCR in Oral Saliva 0.57(0.28–0.85) 6 <0.0001 100 0.148
Positive PCR in Nasal 0.73(0.48–0.98) 1 <0.0001 100 0.033
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Figure 3. Forest plot representation of the extracted data for urine analysis using molecular methods
on leishmaniasis with subgroup analysis on dogs and humans.
Antibody detection has also been carried out using urine, mainly in humans but rarely in dogs. A
high positivity of 92% (95% CI: 87–96) is recorded in humans (Figure 4, lower panel), which is lower
in dogs (62%; 95% CI: 51–72; Figure 4, upper panel). Only two studies on dogs satisfy our inclusion
criteria and were analyzed as contrasted to the 12 studies carried out on humans (Figure 4). The test of
heterogeneity between studies on Ab detection in human urine depicts a rather high heterogeneity
(I2 = 86.48%). A positivity of 74% (95% CI: 64–83) is recorded for antibody detection in humans. The
parasitological method represents a simple way to detect leishmania infection, which has been applied
to dogs suffering from CVL (1 study), and humans (4 studies). An overall positivity of 28% is recorded
(95% CI: 0–76; Figure 5). Antigen detection in urine is used for the diagnosis of visceral leishmaniasis
(see Section 2.2.1). Our meta-analysis highlights a 74% (95% CI: 64–83) positivity for the detection of
antibodies in urine. We have not performed subgroup analysis according to the methodology used
(ELISA, other) or the infecting leishmania species that is reflected by the high heterogeneity (I2 =
94.33%) (Figure 6).
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Figure 6. Forest plot representation of the extracted data for urine analysis using antigen detection
methods with subgroup analysis on human leishmaniasis and Chagas disease.
Human African Trypanosomiasis and Animal Trypanosomiases. Analysis cannot be performed
due to a lack of quantitative data.
Chagas Disease. Ag detection has been carried out several times on patients’ urine and 7
studies satisfying our inclusion criteria were gathered (Figure 6). We recorded a higher positivity for
antigen detection in CD (84%; 95% CI: 69–95) than for Leishmaniasis (74%), see above. Our analysis
further confirms that Ag detection in a patient’s urine represents an interesting fluid for CD and
Leishmanioses diagnosis.
2.3.2. Feces
No quantitative data available.
2.3.3. Saliva/Oral Swab/Sputum
Human and animal leishmaniases. Molecular methods were used to diagnose leishmania infection
using the saliva of humans and dogs. Six studies were collected and data were extracted (3 for dogs
and 3 for humans) (Figure 7). From these data, we recorded an overall positivity of 56% (CI 95%:
31–79), positivity being higher in humans, 75% (CI 95%: 32–100), than in dogs where it is of 40%
(CI 95%: 13–70). Additional data is required to more firmly address the interest of using molecular
methods to detect leishmania parasites using saliva. Data on the detection of antigen in patients
suffering leishmaniasis has been extracted from only one study with a positivity of 74% [129].
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Figure 7. Forest plot representation of the extracted data for saliva analysis using molecular detection
methods for human leishmaniases (A) and antibody ction methods with subgroup analysis for
human African trypanosomiasis and Chagas disease (B).
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Human African Trypanosomiasis and Animal Trypanosomiases. The two studies on HAT
disclosed a positivity of 97% (95% CI: 92–100) for antibody detection in the saliva.
Chagas Disease. Only one study that respected our inclusion criteria was collected. In this study,
a high positivity was recorded, 90%, that points to the need for additional experiments.
2.3.4. Conjunctival Swab/Lacrimal Fluid
Human and animal leishmaniases. Only data on CVL using molecular methods were gathered
during the survey (Figure 8). An overall positivity of 77% was recorded (95% CI; 65–88) and a high
heterogeneity was recorded (I2 91.64%). Data on the use of parasitological (histology) methods was
extracted from one study performed on CVL, with a positivity of 53% (CI 95%: 40–66) [25].
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data are required to further explore the suitability of this fluid for DNA detection and leishmaniasis 
diagnosis. In addition, one study reported the isolation of leishmania parasites in nasal secretion 
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Figure 8. Forest plot representation of the extracted data for conjunctival swab/lacrimal fluid using
molecular detection methods on canine visceral leishmaniasis.
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2.3.7. Nasal Secretion
Human and animal leishmaniases. Molecular methods applied for the detection of Leishmania
genetic material was used on dogs (1 publication) and on humans (1 publication). From these
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publications, we recorded a very high overall positivity of 93% (CI 95%; 86–96) (Figure 9). Additional
data are required to further explore the suitability of this fluid for DNA detection and leishmaniasis
diagnosis. In addition, one study reported the isolation of leishmania parasites in nasal secretion using
parasitological methods, with a positivity of 36% (95% CI: 24–49) [119].
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Figure 9. Forest plot representation of the extracted data for nasal secretion using molecular detection
methods on dogs and human suffering leishmaniasis.
Human African Trypanosomiasis and Ani al Trypanosomiases. Analysis cannot be performed
due to a lack of quantitative data.
Chagas Disease. Analysis cannot be performed due to a lack of quantitative data.
2.3.8. Hair/bristles
Human and animal leishmaniases. During the past 10 years, molecular methods has been applied
to investigate the suitability of hair or bristle to detect Leishmania genetic parasite material. These
experiments were performed on the domestic reservoir of Leishmania (dogs), but also on potential wild
reservoir (hare). In all cases, positivity greater than 60% were recorded. Altogether, our meta-analysis
points to an an overall positivity of 77% (CI 95%: 59–92) (Figure 10). To further investigate the potential
of hair/bristles to be used to detect leishmania infection, additional experiments are required.
Human African Trypanosomiasis and Animal Trypanosomiases. Analysis cannot be performed
due to a lack of quantitative data.
Ch gas Disease. Analysis cannot be performed due to a lack of quantitative data.
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3.2. Information Source
The selection of studies was based on searches (performed in November 2018) in PubMed,
Web of Science, WorldWideScience, SciELO, Embase, and Google, with no specific year range and
language limitation.
3.3. Search
The search was performed using the subject headings “Leishmania”, “Leishmaniasis”,
“Trypanosoma”, “Trypanosomiasis”, and “Chagas disease” combined with several keywords, including
“urine”, “lacrimal”, “conjunctival”, “ocular”, “eyes”, “saliva”, “sputum”, “oral swab”, “ear swab”,
“buccal swab”, “cerumen”, “semen”, “vulvular”, “feces”, “fecal”, “hair”, “skin”, “nasal swab”, “nostril”,
“pharyngeal”, “mucosal”, “milk”, and “sweat”.
An example of the search strategy in PubMed is below:
1. “Leishmania”,
2. “Leishmani sis”,
3. “Trypanosoma”,
4. “Trypanosomiasis”, and
5. “Chagas disease”,
combined with several key words
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6. “urine”,
7. “lacrimal”,
8. “conjunctival”,
9. “ocular”,
10. “eyes”,
11. “saliva”,
12. “sputum”,
13. “oral swab”,
14. “ear swab”,
15. “buccal swab”,
16. “cerumen”,
17. “semen”,
18. “vulvular”,
19. “feces”, “fecal”,
20. “hair”,
21. “skin”,
22. “nasal swab”,
23. “nostril”,
24. “pharyngeal”,
25. “mucosal”,
26. “milk”, and
27. “sweat”.
3.4. Study Selection
We undertook the review with current recommendations reported in 2015 and reported our
findings as per the PRISMA guidelines, taking into account the remarks for “biological” meta-analyses,
which deal with non-human species [378]. We selected studies for inclusion in two stages. In the
first stage, we screened the titles and abstracts of all citations for potentially relevant papers. In the
second, we examined the full texts of these papers. Two independent reviewers (Denis SERENO and
Mohammad AKHOUNDI) performed the screening and the full text and data extraction. For each
record, to ensure an objective assessment of all the included records, the judgements about eligibility,
bias, and applicability were entirely based on the published documents and not on unpublished
background information. In case of discrepent judgement, Denis SERENO took the final decision.
Studies that involved the following topics were eligible for selection:
1- Leishmaniases, Chagas disease, or trypanosomiases
2- Identification and/or diagnosis with molecular, immunological, or parasitological methods
3- Experimentally or naturally acquired infection.
Duplicates and studies that did not include trypanosomatid detection, disease diagnosis, or the
detection of antibodies, antigens, DNA, RNA, or other molecules were ruled out of the systematic review.
For meta-analysis, data were extracted according to the following criteria: (1) the use of
non-invasive biological sampling methods, (2) diagnosis made on the basis of clinical symptoms
and confirmed by various methodologies (PCR, polymerase chain reaction; ELISA, enzyme linked
immnosorbent assay; IFI, indirect mmmunofluorescence; or parasitology), (3) confirmation performed
using biopsy (blood, lymph node, or spleen aspirate); and (4) data available for individual subjects or
grounded according to clinical symptoms and diagnosis confirmation.
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3.5. Data Collection Process and Items
We developed a data collection sheet to gather data items from studies. The data collection
sheets included the following: first author name, the title and article year of publication, country,
methodologies used to diagnose infection, the name of the alternative biological sampling performed,
the total number of samples processed, the total number of positive samples, the total number of
positive samples for alternative biopsies, and the methods of detection used in the non-invasive
biological sampling. The databases containing the data collection sheet are shown as Supplementary
Material (Datacollection S2).
3.6. Statistical Analysis
Effect size in this study was the prevalence and percentage; the variance of the effect size was
not stable because some percentages were near or equal to 100 and some were near zero; therefore,
a Freeman–Tukey double arcsine transformation was used to stabilize the variances [379,380]. We
checked the heterogeneity between studies by the I2 statistic. The random effects model was used to
combine effect sizes among studies. A meta-regression was performed to investigate the diversity
of pooled effect size according to year of publication. Begg and Egger’s tests were used to assess
publication bias in the included studies [381]. Subgroup analysis was performed based on biological
sample origin and methodology. Data were analyzed using Stata computer software version 11.2
(StataCorp, College Station, TX, USA).
4. Conclusions
Literature analysis reveals striking facts and gaps in the usefulness of body fluid secretions and/or
appendages for the diagnosis of infection caused by Trypanosomatidae parasites. Strikingly, we did not
find data on the presence of parasites, DNA, antibodies, or antigens in the sweat of infected patients. We
confirm the interest of antibody and antigen detection methods in urine to diagnose leishmaniases, and
of Antigen detection in the urine of patients suffering CD. Surprisingly a high positivity was recorded
for Leishmania detection when hair was used in combination with molecular methods. This observation,
which relies on a limited number of data, has now to be thoroughly investigated. With some exceptions,
we recorded a serious lack of experimental and clinical investigations on the appropriateness of
alternative biological sampling methodologies for diagnostic purposes. These data are important to set
up new non-invasive diagnosis protocols to track disease evolution and clinical and/or chemotherapy
success. This is surprising because these alternative sampling strategies present a major advantage of
being based on the collection of daily produced biological materials.
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